Document is current
Any future updates will be listed below
-
Authors
Horton, Miles https://orcid.org/0000-0001-5423-0475
Leung, Becky
Nelles, Ricky
Rubic, Matthew
McKinnely, Christopher
Cibich, Alia
Dowling, Mark R.
Hunt, Stewart
Chee, Lynette C. Y. https://orcid.org/0000-0002-4250-4448
Scott, Ashleigh P. https://orcid.org/0000-0001-5574-6713
Ritchie, David S. https://orcid.org/0000-0001-7329-6605
Hiwase, Devendra https://orcid.org/0000-0002-6666-3056
Purtill, Duncan https://orcid.org/0000-0002-0408-8455
Bhattacharya, Abir
Kennedy, Glen A.
Bajel, Ashish https://orcid.org/0000-0002-3755-7334
- License Information
-
More Information
Article History
Received: 27 December 2025
Revised: 14 March 2026
Accepted: 14 April 2026
First Online: 23 April 2026
Competing interests
: MRD has patents and royalties with AbbVie and received consultancy fees from Kite/Gilead and Novartis. LCYC received honoraria and served on advisory boards for Novartis and Otsuka and received consultancy fees and honoraria from Keros Therapeutics. DSR received research funding from BMS, Novartis and Takeda, received consultancy fees from Novartis and served on advisory boards for Novartis, Takeda and Amgen. DH received honoraria from AbbVie, Otsuka and Astellas Pharma. AB received honoraria and served on advisory boards for AbbVie, Amgen and Astellas; received honoraria from Novartis, Pfizer and Takeda; and served on advisory boards for Glaxo-Smith-Kline. The remaining authors declare no competing financial interests.
: This study was approved by the institutional review board of Melbourne Health with a waiver of informed consent (2023.094) with governance approval of the review boards of participating sites. This work was conducted under the Declaration of Helsinki and Australian data regulations.
